Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two
formulations of palonosetron after intravenous administration of palonosetron in healthy
volunteers under fasting conditions.